Is SPNT a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Specialty insurance replacing reinsurance in the mix, with revenue (ttm) at ~$3.0B. The bear case rests on catastrophe and large-loss exposure has not disappeared, and a single heavy wind or wildfire season can erase a year of underwriting margin at a company of this size. Analysts covering it are spread from $25.00 to $31.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Catastrophe and large-loss exposure has not disappeared, and a single heavy wind or wildfire season can erase a year of underwriting margin at a company of this size. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $25.00, +3.1% from the $24.25 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Specialty insurance replacing reinsurance in the mix. Insurance & Services gross written premium rose about 15 percent year over year to roughly $645 million in the second quarter of 2026, while Reinsurance premium fell about 9 percent to roughly $337 million. The most optimistic analyst target on SPNT is $31.00, +27.8% from the $24.25 price. That figure is only reachable if this thesis works close to its best case.

Catastrophe and large-loss exposure has not disappeared, and a single heavy wind or wildfire season can erase a year of underwriting margin at a company of this size. Reserve development is the second exposure: the current streak of favorable releases is a strength today and a comparison problem later, since a company cannot release reserves indefinitely. Pricing across property catastrophe and much of casualty reinsurance has been drifting lower, which is precisely why premium is falling in that segment, and a longer soft market would pressure the 12 to 15 percent operating return target. Ownership is concentrated enough to matter, with entities associated with Daniel Loeb holding roughly 9.5 percent, and take-private speculation has circulated around the name before without a transaction ever being signed. Finally, the trailing headline earnings multiple near 6 times is flattered by non-recurring items including asset sales, so anyone anchoring on it is looking at a number the operating business does not repeat. The most pessimistic published target is $25.00, +3.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

SiriusPoint is a Bermuda-based specialty insurer and reinsurer writing about $3.8 billion of gross premium a year, and the owner of travel medical platform IMG.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Specialty insurance replacing reinsurance in the mix) stalling in the reported numbers rather than in the narrative, the risk above (catastrophe and large-loss exposure has not disappeared, and a single heavy wind or wildfire season can erase a year of underwriting margin at a company of this size) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

SiriusPoint underwrites specialty insurance and reinsurance from Bermuda, writing roughly $3.8 billion of gross premium a year across about ten lines including accident and health, general liability, surety, property and marine. Alongside the underwriting arm it owns International Medical Group, a travel and international health platform that earns fee and commission income.

Yes. SiriusPoint Ltd. common shares trade on the New York Stock Exchange under SPNT, and that is the company's primary listing. The company is incorporated in Bermuda and files full annual and quarterly reports with the SEC as a US domestic filer, so 10-K and 10-Q disclosure is available rather than the lighter foreign private issuer regime.

No common dividend is currently paid. Capital returns run through share repurchases instead, with roughly $295 million returned in the first half of 2026 and a $733 million buyback of the CM Bermuda stake completed in February 2025. Investors looking for income from Bermuda carriers generally look at RenaissanceRe, Arch or Everest, all of which do pay one.